PINK Simplify Health Care ETF
ETF on NYSE (US) · Actively managed · Listing
Changes appear once four weeks of holdings are on file.
Largest holding: United Therapeutics Corporation, 56,237 shares ($32.8M).
| Current positions Top 10 | % of book |
|---|---|
| United Therapeutics Corporation UTHR $32.8M | 9.8% |
| Arcutis Biotherapeutics, Inc. ARQT $29.5M | 8.8% |
| Johnson & Johnson JNJ $26.4M | 7.9% |
| Eli Lilly and Company LLY $18.7M | 5.6% |
| Humana Inc. HUM $17.0M | 5.1% |
| Warby Parker Inc. WRBY $15.5M | 4.6% |
| AbbVie Inc. ABBV $14.5M | 4.3% |
| Gilead Sciences, Inc. GILD $13.2M | 3.9% |
| Avantor, Inc. AVTR $13.0M | 3.9% |
| Jazz Pharmaceuticals plc JAZZ $12.4M | 3.7% |
Slices are % of holdings value.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 86.7% |
| Consumer Cyclical | 4.6% |
| Industrials | 4.0% |
| Basic Materials | 1.7% |
| Technology | 1.0% |
| Unclassified | 2.0% |
| Industries | % of holdings value |
|---|---|
| Biotechnology | 42.5% |
| Drug Manufacturers - General | 17.8% |
| Healthcare Plans | 10.5% |
| Diagnostics & Research | 5.7% |
| Medical Devices | 5.5% |
| Specialty Retail | 4.6% |
| Industrial Distribution | 3.9% |
| Other (5) | 7.5% |
| Unclassified | 2.0% |
Source: the fund's own published holdings, the portfolio of Nov 17, 2026 (simplify.us). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Oct 29, 2026.
The Simplify Health Care ETF (the "Fund" or "PINK") seeks long-term capital appreciation.
Principal investment strategies
The Fund has adopted a non-fundamental policy that, under normal circumstances, the Fund will invest at least 80% of its assets (plus any borrowings for investment purposes) in securities of U.S. health care companies. The Fund defines health care companies as companies included in the Global Industry Classification Standard health care sector. The Fund defines equity securities as common stock, preferred stock, or ETFs that invest in the same. The Fund invests in companies without restriction as to capitalization, including micro-capitalization companies. 1 The Fund will invest in 50 to 100 health care companies. The Fund will use fundamental, bottom-up analysis that seeks to identify high-quality companies and the most compelling investment opportunities. In general, the Fund will follow a growth investment strategy, seeking companies whose earnings are expected to grow faster than inflation and the economy in general. When stock valuations seem unusually high, however, a "value" approach, which gives preference to seemingly undervalued companies, may be emphasized. The Fund generally seeks investments in companies that are developing new and effective medicines, as well as companies whose business models reduce costs or improve quality in health care systems. The Fund may invest in health care companies that do not seek to design or develop treatments for breast cancer. The Adviser may invest in affiliated money market ETFs to manage liquidity. The Fund may invest in repurchase agreements. Repurchase agreements are transactions in which the Fund purchases government securities and simultaneously commits to resell them to the same counterparty at a future time and at a price reflecting a market rate of interest. The Fund's namesake is The Susan G. Komen Breast Cancer Foundation, Inc. (the "Foundation"), a 501(c)(3) charitable foundation. In exchange for the use of its name and logo, Simplify Asset Management Inc., the Fund's investment adviser, will donate its annual management fee for managing the Fund to the Foundation. The Foundation shall use such donation to support its mission, but the Foundation will not participate in or have any influence on the day-to-day operations of the Fund or the Adviser's management of the Fund. The Fund is not organized as a charitable investment trust.
Management and Contact
- Adviser
- Simplify Asset Management Inc.
- Portfolio managers
-
Michael Taylor, Portfolio Manager of the Adviser;
David Berns, PhD, Chief Investment Officer of the Adviser; and Jeff Schwarte, Chief Equity Strategist of the Adviser each serve as a portfolio manager of the Fund.
Mr. Taylor and Dr. Berns have each served the Fund as a portfolio manager since it commenced operations in October 2021.
Mr. Schwarte has served the Fund as portfolio manager since November 2024.
Mr. Taylor, Dr. Berns, and Mr. Schwarte are jointly and primarily responsible for the management of the Fund.
- Phone
- (855) 772-8488
- Website
- simplify.us/etfs
Track Record as of Dec 31, 2025
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | Since Inception | |
|---|---|---|
| Return Before Taxes | 24.07% | 10.05% |
| Return After Taxes on Distributions | 23.68% | 9.80% |
| Return After Taxes on Distributions and Sale of Fund Shares | 14.22% | 7.80% |
| MSCI USA IMI/Health Care Net (USD) Index (reflects no deduction for fees, expenses or taxes) | 14.91% | 4.76% |
| S&P 500 Index (reflects no deduction for fees, expenses or taxes) | 17.88% | 12.66% |
Holdings as of Nov 17, 2026
The full portfolio the fund publishes every business day on its website (simplify.us). Every line is listed: holdings we could identify link to their page, the rest (cash, options, swaps, private shares, securities we do not carry) are shown as the fund prints them. Short positions are negative. Change is the share count against Nov 16, 2026.
54 lines, 53 linked, weights sum to 100.00% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| UNITED THERAPEUTICS CORP D USD 0.01 | UTHR US91307C1027 | Equity | 56,237 | 0 | 9.81% | $ 32.848M |
| ARCUTIS BIOTHERAPEUTICS USD 0.0001 | ARQT US03969K1088 | Equity | 1,077,695 | 0 | 8.80% | $ 29.453M |
| JOHNSON + JOHNSON USD 1.0 | JNJ US4781601046 | Equity | 94,658 | 0 | 7.88% | $ 26.381M |
| LILLY ELI + CO NPV | LLY US5324571083 | Equity | 13,210 | 0 | 5.59% | $ 18.699M |
| HUMANA INC USD 0.166667 | HUM US4448591028 | Equity | 38,405 | 0 | 5.09% | $ 17.026M |
| WARBY PARKER INC USD 0.0001 | WRBY US93403J1060 | Equity | 599,545 | 0 | 4.64% | $ 15.54M |
| ABBVIE INC USD 0.01 | ABBV US00287Y1091 | Equity | 49,605 | 0 | 4.34% | $ 14.525M |
| GILEAD SCIENCES INC USD 0.001 | GILD US3755581036 | Equity | 77,477 | 0 | 3.94% | $ 13.191M |
| AVANTOR INC USD 0.01 | AVTR US05352A1007 | Equity | 859,446 | 0 | 3.90% | $ 13.046M |
| JAZZ PHARMACEUTICALS PLC USD 0.0001 | JAZZ IE00B4Q5ZN47 | Equity | 51,406 | 0 | 3.70% | $ 12.374M |
| QUEST DIAG COM USD0.01 | DGX US74834L1008 | Equity | 47,346 | 0 | 3.63% | $ 12.137M |
| BENITEC BIOPHARMA INC NPV | BNTC US08205P2092 | Equity | 1,398,956 | 0 | 3.41% | $ 11.401M |
| AMGEN INC USD 0.0001 | AMGN US0311621009 | Equity | 20,014 | 0 | 2.74% | $ 9.165M |
| UNITEDHEALTH GROUP INC USD 0.01 | UNH US91324P1021 | Equity | 21,693 | 0 | 2.53% | $ 8.453M |
| GE HEALTHCARE TECHNOLOGIES USD 0.01 | GEHC US36266G1076 | Equity | 89,245 | 0 | 2.18% | $ 7.304M |
| SUMMIT THERAPEUTICS INC USD 0.01 | SMMT US86627T1088 | Equity | 682,491 | 0 | 2.18% | $ 7.282M |
| CARDINAL HEALTH INC NPV | CAH US14149Y1082 | Equity | 25,646 | 0 | 2.14% | $ 7.162M |
| BIOHAVEN LTD NPV | BHVN VGG1110E1079 | Equity | 526,293 | 0 | 2.08% | $ 6.968M |
|
Cash
|
CASH | Cash | 6,706,454.9401 | +2,883,130.0322 | 2.00% | $ 6.706M |
| GUARDANT HEALTH INC USD 0.00001 | GH US40131M1099 | Equity | 46,576 | 0 | 1.99% | $ 6.673M |
| CVS HEALTH CORPORATION USD 0.01 | CVS US1266501006 | Equity | 66,252 | 0 | 1.70% | $ 5.685M |
| PURECYCLE TECHNOLOGIES I USD 0.0001 | PCT US74623V1035 | Equity | 3,178,831 | 0 | 1.69% | $ 5.658M |
| THERMO FISHER SCIENTIFIC IN USD 1.0 | TMO US8835561023 | Equity | 8,068 | 0 | 1.66% | $ 5.541M |
| VERTEX PHARMACEUTICALS INC USD 0.01 | VRTX US92532F1003 | Equity | 9,980 | 0 | 1.59% | $ 5.331M |
| ESTABLISHMENT LABS HOLDINGS USD 1.0 | ESTA VGG312491084 | Equity | 57,661 | 0 | 1.20% | $ 4.008M |
| COOPER COS INC USD 0.1 | COO US2166485019 | Equity | 57,659 | 0 | 1.05% | $ 3.501M |
| PRAXIS PRECISION MEDICIN USD 0.0001 | PRAX US74006W2070 | Equity | 10,943 | 0 | 1.00% | $ 3.338M |
| VEEVA SYS INC USD 0.00001 | VEEV US9224751084 | Equity | 11,212 | 0 | 0.97% | $ 3.234M |
| VAXCYTE INC USD 0.001 | PCVX US92243G1085 | Equity | 53,169 | 0 | 0.94% | $ 3.158M |
| SCHEIN HENRY INC USD 0.01 | HSIC US8064071025 | Equity | 36,319 | 0 | 0.90% | $ 3.012M |
| LEGEND BIOTECH CORP USD 0.0001 ADR | LEGN US52490G1022 | Equity | 186,947 | 0 | 0.90% | $ 3.012M |
| ELEVANCE HEALTH INC USD 0.01 | ELV US0367521038 | Equity | 6,911 | 0 | 0.90% | $ 2.999M |
| DANAHER CORP USD 0.01 | DHR US2358511028 | Equity | 9,089 | 0 | 0.61% | $ 2.052M |
| EDWARDS LI COM USD1 | EW US28176E1082 | Equity | 17,801 | 0 | 0.56% | $ 1.877M |
| TG THERAPEUTICS INC USD 0.001 | TGTX US88322Q1085 | Equity | 20,283 | 0 | 0.38% | $ 1.272M |
| AGILON HEALTH INC USD 0.01 | AGL US00857U2069 | Equity | 8,038 | 0 | 0.28% | $ 925.978K |
| STRYKER CORP USD 0.1 | SYK US8636671013 | Equity | 2,148 | 0 | 0.20% | $ 682.076K |
| FULCRUM THERAPEUTICS INC USD 0.001 | FULC US3596161097 | Equity | 146,506 | 0 | 0.16% | $ 549.398K |
| NEUROCRINE BIOSCIENCES IN USD 0.001 | NBIX US64125C1099 | Equity | 3,162 | 0 | 0.16% | $ 524.639K |
| ZIMMER BIOMET HLDGS INC USD 0.01 | ZBH US98956P1021 | Equity | 4,191 | 0 | 0.13% | $ 427.859K |
| ABBOTT LABS NPV | ABT US0028241000 | Equity | 3,243 | 0 | 0.10% | $ 339.575K |
| FLUOR CORP NEW USD 0.01 | FLR US3434121022 | Equity | 5,944 | 0 | 0.09% | $ 287.155K |
| ICON PLC EUR 0.06 | ICLR IE0005711209 | Equity | 1,431 | 0 | 0.08% | $ 279.074K |
| TELEFLEX INC USD 1.0 | TFX US8793691069 | Equity | 1,401 | 0 | 0.07% | $ 223.53K |
| SAREPTA THERAPEUTICS INC USD 0.0001 | SRPT US8036071004 | Equity | 7,336 | 0 | 0.03% | $ 108.353K |
| VERALTO CORP USD 0.01 | VLTO US92338C1036 | Equity | 734 | 0 | 0.03% | $ 86.891K |
| REGENERON PHARMACEUTICALS USD 0.001 | REGN US75886F1075 | Equity | 78 | 0 | 0.02% | $ 74.705K |
| BRISTOL MYERS SQUIBB CO USD 0.1 | BMY US1101221083 | Equity | 1,049 | 0 | 0.02% | $ 64.356K |
| GRAIL INC USD 0.01 | GRAL US3847471014 | Equity | 478 | 0 | 0.02% | $ 50.611K |
| ABIVAX SA EUR 0.01 ADR | ABVX US00370M1036 | Equity | 220 | 0 | 0.01% | $ 18.062K |
| INSMED INC USD 0.01 | INSM US4576693075 | Equity | 148 | 0 | 0.01% | $ 18.035K |
| EMBECTA CORP USD 0.01 | EMBC US29082K1051 | Equity | 2,794 | 0 | 0.01% | $ 17.183K |
| NOVO-NORDISK A S DKK 10.0 ADR | NVO US6701002056 | Equity | 351 | 0 | 0.00% | $ 14.286K |
| SYNDAX PHARMACEUTICALS I USD 0.0001 | SNDX US87164F1057 | Equity | 774 | 0 | 0.00% | $ 7,120.80 |
Trades Nov 16, 2026 to Nov 17, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
| PACIRA BIOSCIENCES INC USD 0.001 | PCRX | Closed | 79,150 | — | −79,150 | $ -2.887M |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up